EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality

Maxine Ajimi, Benjamin Webb iD, Graham M Wheeler, Jayne Marshall, Adrian P Mander

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 19.04.2026. Verfasst von Maxine Ajimi und 4 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug combinations, where two drugs are co‐administered, are being explored widely within Phase I trials in oncology. These trials aim to identify the maximum tolerated dose combination (MTDC) by adapting the dose of both treatments based on current trial data. Various methods have been proposed to inform how escalation decisions are made within a trial. We propose a model‐based design which aims to adapt the dose combination that participants receive to a level that maximises the information gained from each move across the toxicity surface, subject to admissibility and escalation constraints (penalised D‐Optimality strategy). We simulated multiple different scenarios, and the penalised D‐Optimality strategy is shown to have similar operating characteristics to the Interval approach, which is widely used within Phase I oncology trials. Furthermore, the penalised D‐Optimality strategy shows further exploration across the toxicity surface, providing the potential to identify multiple MTDCs, further characterise the risk–benefit profile and provide flexibility for dose selection in future trials. We also show how priors of the two drugs can be specified to show a favoured escalation route if pre‐clinical data suggests this.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicResearch DesignAntineoplastic Combined Chemotherapy ProtocolsHumansBayes TheoremMaximum Tolerated DoseDose-Response Relationship, DrugLogistic ModelsComputer SimulationDrug Combinations

Substanzen

Drug Combinations

Autor:innen und Institutionen

  • AstraZeneca, Cambridge, UK.
  • GlaxoSmithKline, London, UK.

ORCID-Profile: Benjamin Webb

Zitieren

APA

Ajimi, M., Webb, B., Wheeler, G. M., Marshall, J., & Mander, A. P. (2026). A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70071

Vancouver

Ajimi M, Webb B, Wheeler GM, Marshall J, Mander AP. A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70071

BibTeX
@article{Ajimi2026,
  author = {Ajimi, Maxine and Webb, Benjamin and Wheeler, Graham M and Marshall, Jayne and Mander, Adrian P},
  title = {A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70071}
}
Kostenlos starten →